|
PL1725528T3
(pl)
|
2004-03-11 |
2013-12-31 |
4Sc Ag |
Sulfonylopirole jako inhibitory HDAC
|
|
CA2566094A1
(en)
|
2004-05-26 |
2005-12-08 |
Eisai R & D Management Co., Ltd. |
Cinnamide compound
|
|
US7781478B2
(en)
|
2004-07-14 |
2010-08-24 |
Ptc Therapeutics, Inc. |
Methods for treating hepatitis C
|
|
MY179032A
(en)
|
2004-10-25 |
2020-10-26 |
Cancer Research Tech Ltd |
Ortho-condensed pyridine and pyrimidine derivatives (e.g.purines) as protein kinase inhibitors
|
|
AU2005297966B2
(en)
|
2004-10-26 |
2010-12-23 |
Eisai R & D Management Co., Ltd. |
Amorphous object of cinnamide compound
|
|
WO2006076706A1
(en)
|
2005-01-14 |
2006-07-20 |
Millennium Pharmaceuticals, Inc. |
Cinnamide and hydrocinnamide derivatives with raf-kinase inhibitory activity
|
|
CA2599538C
(en)
|
2005-03-15 |
2013-07-30 |
Nycomed Gmbh |
N-sulphonylpyrroles and their use as histone deacetylase inhibitors
|
|
CR9465A
(es)
*
|
2005-03-25 |
2008-06-19 |
Surface Logix Inc |
Compuestos mejorados farmacocineticamente
|
|
FR2886844B1
(fr)
*
|
2005-06-09 |
2007-09-14 |
Oreal |
Utilisation de composes 2-oxy-acetamide pour favoriser et/ou induire et/ou stimuler la pigmentation des matieres keratiniques et/ou limiter leur depigmentation et/ou leur blanchiment
|
|
ES2580108T3
(es)
|
2005-07-11 |
2016-08-19 |
Aerie Pharmaceuticals, Inc |
Compuestos de isoquinolina
|
|
AU2006298881A1
(en)
|
2005-09-21 |
2007-04-12 |
4Sc Ag |
Sulphonylpyrrole hydrochloride salts as histone deacetylases inhibitors
|
|
ES2381962T3
(es)
|
2005-09-21 |
2012-06-04 |
4Sc Ag |
Nuevos sulfonilpirroles como inhibidores de las HDAC
|
|
EP1953151A4
(en)
*
|
2005-11-18 |
2010-06-02 |
Eisai R&D Man Co Ltd |
SALTS FROM A CYNNAMIDE COMPOUND OR SOLVATE THEREOF
|
|
CN101309916A
(zh)
*
|
2005-11-18 |
2008-11-19 |
卫材R&D管理有限公司 |
制备肉桂酰胺衍生物的方法
|
|
BRPI0618814A2
(pt)
*
|
2005-11-24 |
2014-04-29 |
Eisai R&D Man Co Ltd |
Composto ou um sal farmacologicamente aceitável do mesmo, e, agente farmacêutico
|
|
TWI370130B
(en)
|
2005-11-24 |
2012-08-11 |
Eisai R&D Man Co Ltd |
Two cyclic cinnamide compound
|
|
TWI630207B
(zh)
|
2005-12-13 |
2018-07-21 |
英塞特控股公司 |
作為傑納斯激酶（ＪＡＮＵＳ ＫＩＮＡＳＥ）抑制劑之經雜芳基取代之吡咯并〔２，３-ｂ〕吡啶及吡咯并〔２，３-ｂ〕嘧啶
|
|
US7989461B2
(en)
|
2005-12-23 |
2011-08-02 |
Amgen Inc. |
Substituted quinazolinamine compounds for the treatment of cancer
|
|
WO2007083904A1
(en)
*
|
2006-01-18 |
2007-07-26 |
Lg Household & Health Care Ltd. |
C-kit activation inhibitor, skin whitening compound and composition for skin whitening containing the same
|
|
TWI378091B
(en)
|
2006-03-09 |
2012-12-01 |
Eisai R&D Man Co Ltd |
Multi-cyclic cinnamide derivatives
|
|
WO2007125321A2
(en)
|
2006-04-25 |
2007-11-08 |
Astex Therapeutics Limited |
Purine and deazapurine derivatives as pharmaceutical compounds
|
|
AU2007252644A1
(en)
*
|
2006-05-19 |
2007-11-29 |
Eisai R & D Management Co., Ltd. |
Heterocyclic type cinnamide derivative
|
|
US7737141B2
(en)
|
2006-07-28 |
2010-06-15 |
Eisai R&D Management Co., Ltd. |
Prodrug of cinnamide compound
|
|
CA2664335C
(en)
|
2006-09-20 |
2014-12-02 |
Boehringer Ingelheim International Gmbh |
Rho kinase inhibitors
|
|
US8314119B2
(en)
|
2006-11-06 |
2012-11-20 |
Abbvie Inc. |
Azaadamantane derivatives and methods of use
|
|
US8455513B2
(en)
|
2007-01-10 |
2013-06-04 |
Aerie Pharmaceuticals, Inc. |
6-aminoisoquinoline compounds
|
|
CL2008000582A1
(es)
*
|
2007-02-28 |
2008-06-27 |
Eisai R&D Man Co Ltd |
Compuestos ciclicos derivados de oximorfolina condensados; farmacos que comprenden a dichos compuestos; y su uso para tratar enfermedad de alzheimer, demencia senil, sindrome de down o amiloidosis.
|
|
ES2534573T3
(es)
|
2007-04-06 |
2015-04-24 |
Neurocrine Biosciences, Inc. |
Antagonistas del receptor de la hormona liberadora de gonadotropina y métodos relacionados con los mismos
|
|
CL2008000986A1
(es)
|
2007-04-06 |
2008-10-17 |
Neurocrine Biosciences Inc |
COMPUESTO DERIVADO DE HETEROCICLOS DE NITROGENO, AGONISTAS DEL RECEPTOR GnRH; COMPOSICION FARMACEUTICA QUE COMPRENDE A DICHO COMPUESTO; Y USO PARA TRATAR UNA AFECCION RELACIONADA CON LAS HORMONAS SEXUALES, ENDOMETRIOSIS, DISMENORREA, ENFERMEDAD DE OV
|
|
WO2008140111A1
(ja)
*
|
2007-05-16 |
2008-11-20 |
Eisai R & D Management Co., Ltd. |
シンナミド誘導体のワンポット製造方法
|
|
EP3070090B1
(en)
|
2007-06-13 |
2018-12-12 |
Incyte Holdings Corporation |
Use of salts of the janus kinase inhibitor (r)-3-(4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-1h- pyrazol-1-yl)-3- cyclopentylpropanenitrile
|
|
AU2008289037B2
(en)
|
2007-08-22 |
2012-03-01 |
Novartis Ag |
5- (4- (haloalkoxy) phenyl) pyrimidine-2-amine compounds and compositions as kinase inhibitors
|
|
US7935815B2
(en)
|
2007-08-31 |
2011-05-03 |
Eisai R&D Management Co., Ltd. |
Imidazoyl pyridine compounds and salts thereof
|
|
CA2694401C
(en)
|
2007-08-31 |
2012-12-04 |
Eisai R&D Management Co., Ltd. |
Polycyclic compound
|
|
AU2008309383B2
(en)
|
2007-10-11 |
2012-04-19 |
Astrazeneca Ab |
Pyrrolo [2, 3 -D] pyrimidin derivatives as protein kinase B inhibitors
|
|
JP5544296B2
(ja)
|
2007-11-16 |
2014-07-09 |
ライジェル ファーマシューティカルズ， インコーポレイテッド |
代謝障害のためのカルボキサミド、スルホンアミド、およびアミン化合物
|
|
ES2553340T3
(es)
|
2007-12-12 |
2015-12-07 |
Rigel Pharmaceuticals, Inc. |
Compuestos de carboxamida, sulfonamida y amina para trastornos metabólicos
|
|
US8487121B2
(en)
*
|
2007-12-18 |
2013-07-16 |
Glenmark Pharmaceuticals S.A. |
Chromane derivatives as TRPV3 modulators
|
|
US8455514B2
(en)
|
2008-01-17 |
2013-06-04 |
Aerie Pharmaceuticals, Inc. |
6-and 7-amino isoquinoline compounds and methods for making and using the same
|
|
WO2009096349A1
(ja)
*
|
2008-01-28 |
2009-08-06 |
Eisai R & D Management Co., Ltd. |
結晶性のシンナミド化合物またはその塩
|
|
US8193202B2
(en)
|
2008-04-21 |
2012-06-05 |
Lexicon Pharmaceuticals, Inc. |
LIMK2 inhibitors, compositions comprising them, and methods of their use
|
|
MX2010011288A
(es)
|
2008-04-23 |
2010-11-09 |
Rigel Pharmaceuticals Inc |
Compuestos de carboxamida para el tratamiento de trastornos metabolicos.
|
|
CA2728405A1
(en)
|
2008-06-17 |
2010-01-14 |
Glenmark Pharmaceuticals, S.A. |
Chromane derivatives as trpv3 modulators
|
|
US8450344B2
(en)
|
2008-07-25 |
2013-05-28 |
Aerie Pharmaceuticals, Inc. |
Beta- and gamma-amino-isoquinoline amide compounds and substituted benzamide compounds
|
|
EP2384326B1
(en)
*
|
2008-08-20 |
2014-04-23 |
Zoetis LLC |
Pyrrolo[2,3-d]pyrimidine compounds
|
|
WO2010052448A2
(en)
*
|
2008-11-05 |
2010-05-14 |
Ucb Pharma S.A. |
Fused pyrazine derivatives as kinase inhibitors
|
|
ES2834451T3
(es)
|
2009-05-01 |
2021-06-17 |
Aerie Pharmaceuticals Inc |
Inhibidores de mecanismo doble para el tratamiento de enfermedades
|
|
AR076794A1
(es)
|
2009-05-22 |
2011-07-06 |
Incyte Corp |
Derivados de n-(hetero)aril-pirrolidina de pirazol-4-il-pirrolo [2,3-d]pirimidinas y pirrol-3-il-pirrolo [2,3-d ]pirimidinas como inhibidores de la quinasa janus y composiciones farmaceuticas que los contienen
|
|
EP3643312A1
(en)
|
2009-05-22 |
2020-04-29 |
Incyte Holdings Corporation |
3-[4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-1h-pyrazol-1-yl]octane- or heptane-nitrile as jak inhibitors
|
|
AR078012A1
(es)
|
2009-09-01 |
2011-10-05 |
Incyte Corp |
Derivados heterociclicos de las pirazol-4-il- pirrolo (2,3-d) pirimidinas como inhibidores de la quinasa janus
|
|
EA201290147A1
(ru)
*
|
2009-10-15 |
2012-11-30 |
Пфайзер Инк. |
Пирроло[2,3-d]пиримидиновые соединения
|
|
US20110130415A1
(en)
*
|
2009-12-01 |
2011-06-02 |
Rajinder Singh |
Protein kinase c inhibitors and uses thereof
|
|
US8198285B2
(en)
|
2010-01-19 |
2012-06-12 |
Astrazeneca Ab |
Pyrazine derivatives
|
|
EP3050882B1
(en)
|
2010-03-10 |
2018-01-31 |
Incyte Holdings Corporation |
Piperidin-4-yl azetidine derivatives as jak1 inhibitors
|
|
SG10201503983QA
(en)
|
2010-05-21 |
2015-06-29 |
Incyte Corp |
Topical Formulation for a JAK Inhibitor
|
|
CN103180321A
(zh)
|
2010-09-23 |
2013-06-26 |
Abbvie公司 |
氮杂金刚烷衍生物的一水合物
|
|
US9034884B2
(en)
|
2010-11-19 |
2015-05-19 |
Incyte Corporation |
Heterocyclic-substituted pyrrolopyridines and pyrrolopyrimidines as JAK inhibitors
|
|
CN103415515B
(zh)
|
2010-11-19 |
2015-08-26 |
因塞特公司 |
作为jak抑制剂的环丁基取代的吡咯并吡啶和吡咯并嘧啶衍生物
|
|
BR112013025410A2
(pt)
|
2011-04-01 |
2016-12-20 |
Astrazeneca Ab |
tratamento terapêutico
|
|
PE20140832A1
(es)
|
2011-06-20 |
2014-07-14 |
Incyte Corp |
Derivados de azetidinil fenil, piridil o pirazinil carboxamida como inhibidores de jak
|
|
TW201313721A
(zh)
|
2011-08-18 |
2013-04-01 |
Incyte Corp |
作為ｊａｋ抑制劑之環己基氮雜環丁烷衍生物
|
|
UA111854C2
(uk)
|
2011-09-07 |
2016-06-24 |
Інсайт Холдінгс Корпорейшн |
Способи і проміжні сполуки для отримання інгібіторів jak
|
|
CA2856646C
(en)
|
2011-11-30 |
2020-01-14 |
Astrazeneca Ab |
Combination treatment of cancer
|
|
WO2013088315A1
(en)
|
2011-12-15 |
2013-06-20 |
Pfizer Limited |
Sulfonamide derivatives
|
|
AU2013204533B2
(en)
|
2012-04-17 |
2017-02-02 |
Astrazeneca Ab |
Crystalline forms
|
|
TW201406761A
(zh)
|
2012-05-18 |
2014-02-16 |
Incyte Corp |
做爲ｊａｋ抑制劑之哌啶基環丁基取代之吡咯并吡啶及吡咯并嘧啶衍生物
|
|
EP2858501A4
(en)
*
|
2012-05-22 |
2015-12-09 |
Merck Sharp & Dohme |
TRKA KINASE INHIBITORS, COMPOSITIONS AND METHOD THEREFOR
|
|
PL2919766T3
(pl)
|
2012-11-15 |
2021-10-04 |
Incyte Holdings Corporation |
Postacie dawkowania ruksolitynibu o przedłużonym uwalnianiu
|
|
TW201444798A
(zh)
|
2013-02-28 |
2014-12-01 |
必治妥美雅史谷比公司 |
作爲強效ｒｏｃｋ１及ｒｏｃｋ２抑制劑之苯基吡唑衍生物
|
|
EP2961746B1
(en)
|
2013-02-28 |
2018-01-03 |
Bristol-Myers Squibb Company |
Phenylpyrazole derivatives as potent rock1 and rock2 inhibitors
|
|
CN105189509B
(zh)
|
2013-03-06 |
2017-12-19 |
因赛特公司 |
用于制备jak抑制剂的方法及中间体
|
|
EP2976080B1
(en)
|
2013-03-15 |
2019-12-25 |
Aerie Pharmaceuticals, Inc. |
Conjugates of isoquinoline compounds and prostaglandins
|
|
SG10201912203XA
(en)
|
2013-08-07 |
2020-02-27 |
Incyte Corp |
Sustained release dosage forms for a jak1 inhibitor
|
|
CN103910715B
(zh)
*
|
2014-03-26 |
2016-03-02 |
深圳翰宇药业股份有限公司 |
一种别嘌醇杂质c的合成方法
|
|
US9527812B2
(en)
|
2014-05-01 |
2016-12-27 |
Northwestern University |
N-heterocyclic carbene-catalyzed synthesis of 2-aryl indoles
|
|
EP3140298A1
(en)
|
2014-05-07 |
2017-03-15 |
Pfizer Inc. |
Tropomyosin-related kinase inhibitors
|
|
WO2015184305A1
(en)
|
2014-05-30 |
2015-12-03 |
Incyte Corporation |
TREATMENT OF CHRONIC NEUTROPHILIC LEUKEMIA (CNL) AND ATYPICAL CHRONIC MYELOID LEUKEMIA (aCML) BY INHIBITORS OF JAK1
|
|
EA037299B1
(ru)
|
2014-09-17 |
2021-03-05 |
Селджен Кар Ллс |
Ингибиторы mk2 и их применения
|
|
ES2989326T3
(es)
|
2015-10-21 |
2024-11-26 |
Otsuka Pharma Co Ltd |
Compuestos de benzolactama como inhibidores de la proteína cinasa
|
|
EP3376870B1
(en)
|
2015-11-17 |
2021-08-11 |
Aerie Pharmaceuticals, Inc. |
Process for the preparation of kinase inhibitors and intermediates thereof
|
|
US9643927B1
(en)
|
2015-11-17 |
2017-05-09 |
Aerie Pharmaceuticals, Inc. |
Process for the preparation of kinase inhibitors and intermediates thereof
|
|
EP3390387B1
(en)
|
2015-12-18 |
2021-11-17 |
Bayer Pharma Aktiengesellschaft |
Heteroarylbenzimidazole compounds
|
|
HRP20202078T1
(hr)
*
|
2016-05-12 |
2021-02-19 |
Boehringer Ingelheim International Gmbh |
Derivati piridinila, njihovi farmaceutski pripravci i njihove uporabe kao aoc3-inhibitori
|
|
WO2017207534A1
(en)
|
2016-06-03 |
2017-12-07 |
Bayer Pharma Aktiengesellschaft |
Substituted heteroarylbenzimidazole compounds
|
|
CN107663202B
(zh)
*
|
2016-07-29 |
2020-09-04 |
西华大学 |
3-(脲基-甲基)-4-芳基-吡啶衍生物及其制备方法和作为抗肝癌药物的应用
|
|
MX2019002396A
(es)
|
2016-08-31 |
2019-07-08 |
Aerie Pharmaceuticals Inc |
Composiciones oftalmicas.
|
|
MY199759A
(en)
|
2016-09-02 |
2023-11-21 |
Tisento Therapeutics Inc |
Fused bicyclic sgc stimulators
|
|
WO2018165520A1
(en)
|
2017-03-10 |
2018-09-13 |
Vps-3, Inc. |
Metalloenzyme inhibitor compounds
|
|
JP2020515583A
(ja)
|
2017-03-31 |
2020-05-28 |
アエリエ ファーマシューティカルズ インコーポレイテッド |
アリールシクロプロピル−アミノ−イソキノリニルアミド化合物
|
|
GB201706327D0
(en)
|
2017-04-20 |
2017-06-07 |
Otsuka Pharma Co Ltd |
A pharmaceutical compound
|
|
WO2018204532A1
(en)
*
|
2017-05-03 |
2018-11-08 |
Vivace Therapeutics, Inc. |
Non-fused tricyclic compounds
|
|
WO2019113487A1
(en)
|
2017-12-08 |
2019-06-13 |
Incyte Corporation |
Low dose combination therapy for treatment of myeloproliferative neoplasms
|
|
EP3746429B1
(en)
|
2018-01-30 |
2022-03-09 |
Incyte Corporation |
Processes for preparing (1-(3-fluoro-2-(trifluoromethyl)isonicotinyl)piperidine-4-one)
|
|
US20190292188A1
(en)
|
2018-02-27 |
2019-09-26 |
Incyte Corporation |
Imidazopyrimidines and triazolopyrimidines as a2a / a2b inhibitors
|
|
PT3773593T
(pt)
|
2018-03-30 |
2024-06-25 |
Incyte Corp |
Tratamento da hidradenite supurativa com inibidores de jak
|
|
MA52940A
(fr)
|
2018-05-18 |
2021-04-28 |
Incyte Corp |
Dérivés de pyrimidine fusionnés utilisés en tant qu'inhibiteurs de a2a/a2b
|
|
CN113166153B
(zh)
|
2018-07-05 |
2024-11-01 |
因赛特公司 |
作为a2a/a2b抑制剂的稠合吡嗪衍生物
|
|
AU2019337703B2
(en)
|
2018-09-14 |
2023-02-02 |
Aerie Pharmaceuticals, Inc. |
Aryl cyclopropyl-amino-isoquinolinyl amide compounds
|
|
US11066404B2
(en)
|
2018-10-11 |
2021-07-20 |
Incyte Corporation |
Dihydropyrido[2,3-d]pyrimidinone compounds as CDK2 inhibitors
|
|
CN112955214B
(zh)
|
2018-10-29 |
2024-05-07 |
勃林格殷格翰国际有限公司 |
吡啶基磺酰胺衍生物、药物组合物及其用途
|
|
CN112955215B
(zh)
|
2018-10-29 |
2024-05-17 |
勃林格殷格翰国际有限公司 |
吡啶基磺酰胺衍生物、药物组合物及其用途
|
|
TWI829857B
(zh)
|
2019-01-29 |
2024-01-21 |
美商英塞特公司 |
作為a2a / a2b抑制劑之吡唑并吡啶及三唑并吡啶
|
|
NL2022471B1
(en)
|
2019-01-29 |
2020-08-18 |
Vationpharma B V |
Solid state forms of oclacitinib
|
|
US11384083B2
(en)
|
2019-02-15 |
2022-07-12 |
Incyte Corporation |
Substituted spiro[cyclopropane-1,5′-pyrrolo[2,3-d]pyrimidin]-6′(7′h)-ones as CDK2 inhibitors
|
|
US11472791B2
(en)
|
2019-03-05 |
2022-10-18 |
Incyte Corporation |
Pyrazolyl pyrimidinylamine compounds as CDK2 inhibitors
|
|
WO2020205560A1
(en)
|
2019-03-29 |
2020-10-08 |
Incyte Corporation |
Sulfonylamide compounds as cdk2 inhibitors
|
|
US11440914B2
(en)
|
2019-05-01 |
2022-09-13 |
Incyte Corporation |
Tricyclic amine compounds as CDK2 inhibitors
|
|
US11447494B2
(en)
|
2019-05-01 |
2022-09-20 |
Incyte Corporation |
Tricyclic amine compounds as CDK2 inhibitors
|
|
CN114727974A
(zh)
|
2019-07-30 |
2022-07-08 |
艾科尼佐治疗股份有限公司 |
Hdac6抑制剂及其用途
|
|
MX2022001940A
(es)
|
2019-08-14 |
2022-05-10 |
Incyte Corp |
Compuestos de imidazolil pirimidinilamina como inhibidores de cdk2.
|
|
AU2020340427A1
(en)
*
|
2019-08-29 |
2022-03-31 |
Hibercell, Inc. |
PERK inhibiting compounds
|
|
CN119930610A
(zh)
|
2019-10-11 |
2025-05-06 |
因赛特公司 |
作为cdk2抑制剂的双环胺
|
|
JP7711068B2
(ja)
|
2019-12-24 |
2025-07-22 |
カルナバイオサイエンス株式会社 |
ジアシルグリセロールキナーゼ調節化合物
|
|
IL295023A
(en)
|
2020-02-14 |
2022-09-01 |
Jounce Therapeutics Inc |
Antibodies and fusion proteins that bind to ccr8 and their uses
|
|
US11833155B2
(en)
|
2020-06-03 |
2023-12-05 |
Incyte Corporation |
Combination therapy for treatment of myeloproliferative neoplasms
|
|
US11981671B2
(en)
|
2021-06-21 |
2024-05-14 |
Incyte Corporation |
Bicyclic pyrazolyl amines as CDK2 inhibitors
|
|
AU2022299051B2
(en)
|
2021-06-23 |
2025-03-13 |
Gilead Sciences, Inc. |
Diacylglyercol kinase modulating compounds
|
|
AU2022298639C1
(en)
|
2021-06-23 |
2025-07-17 |
Gilead Sciences, Inc. |
Diacylglyercol kinase modulating compounds
|
|
KR20240025616A
(ko)
|
2021-06-23 |
2024-02-27 |
길리애드 사이언시즈, 인코포레이티드 |
다이아실글리세롤 키나제 조절 화합물
|
|
KR20240005901A
(ko)
|
2021-06-23 |
2024-01-12 |
길리애드 사이언시즈, 인코포레이티드 |
디아실글리세롤 키나제 조절 화합물
|
|
JP2024539252A
(ja)
|
2021-10-28 |
2024-10-28 |
ギリアード サイエンシーズ， インコーポレイテッド |
ピリジジン－３（２ｈ）－オン誘導体
|
|
CA3235986A1
(en)
|
2021-10-29 |
2023-05-04 |
Gilead Science, Inc. |
Cd73 compounds
|
|
US11976073B2
(en)
|
2021-12-10 |
2024-05-07 |
Incyte Corporation |
Bicyclic amines as CDK2 inhibitors
|
|
EP4452414A2
(en)
|
2021-12-22 |
2024-10-30 |
Gilead Sciences, Inc. |
Ikaros zinc finger family degraders and uses thereof
|
|
EP4667056A1
(en)
|
2021-12-22 |
2025-12-24 |
Gilead Sciences, Inc. |
Ikaros zinc finger family degraders and uses thereof
|
|
TW202340168A
(zh)
|
2022-01-28 |
2023-10-16 |
美商基利科學股份有限公司 |
Ｐａｒｐ７抑制劑
|
|
LT4245756T
(lt)
|
2022-03-17 |
2024-11-25 |
Gilead Sciences, Inc. |
Ikaros cinko pirštų šeimos skaidymo medžiagos ir jų panaudojimas
|
|
US20230374036A1
(en)
|
2022-04-21 |
2023-11-23 |
Gilead Sciences, Inc. |
Kras g12d modulating compounds
|
|
IL317958A
(en)
|
2022-07-01 |
2025-02-01 |
Gilead Sciences Inc |
CD73 compounds
|
|
EP4638436A1
(en)
|
2022-12-22 |
2025-10-29 |
Gilead Sciences, Inc. |
Prmt5 inhibitors and uses thereof
|
|
EP4695260A1
(en)
|
2023-04-11 |
2026-02-18 |
Gilead Sciences, Inc. |
Kras modulating compounds
|
|
KR20250175331A
(ko)
|
2023-04-21 |
2025-12-16 |
길리애드 사이언시즈, 인코포레이티드 |
Prmt5 억제제 및 이의 용도
|
|
AU2024306338A1
(en)
|
2023-06-30 |
2026-01-08 |
Gilead Sciences, Inc. |
Kras modulating compounds
|
|
AU2024297978A1
(en)
|
2023-07-26 |
2026-02-05 |
Gilead Sciences, Inc. |
Parp7 inhibitors
|
|
AU2024300557A1
(en)
|
2023-07-26 |
2026-02-05 |
Gilead Sciences, Inc. |
Parp7 inhibitors
|
|
WO2025054530A1
(en)
|
2023-09-08 |
2025-03-13 |
Gilead Sciences, Inc. |
Pyrimidine-containing polycyclic derivatives as kras g12d modulating compounds
|
|
US20250101042A1
(en)
|
2023-09-08 |
2025-03-27 |
Gilead Sciences, Inc. |
Kras g12d modulating compounds
|
|
US20250154172A1
(en)
|
2023-11-03 |
2025-05-15 |
Gilead Sciences, Inc. |
Prmt5 inhibitors and uses thereof
|
|
WO2025137640A1
(en)
|
2023-12-22 |
2025-06-26 |
Gilead Sciences, Inc. |
Azaspiro wrn inhibitors
|
|
WO2025245003A1
(en)
|
2024-05-21 |
2025-11-27 |
Gilead Sciences, Inc. |
Prmt5 inhibitors and uses thereof
|
|
WO2026039365A1
(en)
|
2024-08-12 |
2026-02-19 |
Gilead Sciences, Inc. |
Kras modulating compounds
|